神経変調療法用装置の世界市場：脳深部刺激療法、脊髄刺激療法、経頭蓋磁気刺激法...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19

2 RESEARCH METHODOLOGY 20
2.1 RESEARCH METHODOLOGY STEPS 20
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 21
2.2.1 SECONDARY RESEARCH 21
2.2.2 PRIMARY RESEARCH 22
2.2.2.1 Key data from primary sources 23
2.2.2.2 Key Insights from primary sources 23
2.2.2.3 Key industry insights 24
2.2.3 MARKET SIZE ESTIMATION METHODOLOGY 24
2.2.4 RESEARCH DESIGN 26
2.2.5 MARKET DATA VALIDATION AND TRIANGULATION 27
2.2.6 ASSUMPTIONS FOR THE STUDY 28

3 EXECUTIVE SUMMARY 29
3.1 INTRODUCTION 29
3.2 CURRENT SCENARIO 30
3.3 FUTURE OUTLOOK 31
3.4 CONCLUSION 34

4 PREMIUM INSIGHTS 35
4.1 GLOBAL NEUROMODULATION MARKET OVERVIEW 35
4.2 GLOBAL NEUROMODULATION MARKET, BY TYPE 35
4.3 GEOGRAPHIC ANALYSIS OF THE DEEP BRAIN STIMULATION MARKET, BY APPLICATION 36
4.4 INTERNAL NEUROMODULATION MARKET, BY MODALITY 37
4.5 GEOGRAPHICAL SNAPSHOT OF THE NEUROMODULATION MARKET 38
 
5 MARKET OVERVIEW 39
5.1 INTRODUCTION 40
5.2 MARKET SEGMENTATION 41
5.3 MARKET DYNAMICS 42
5.3.1 DRIVERS 42
5.3.1.1 Rising prevalence of neurological disorders to spur market growth 42
5.3.1.2 Unprecedented increase in the aging population to fuel market growth 43
5.3.1.3 Expanded target applications and new indications are expected to stimulate the growth of neuromodulation devices 43
5.3.1.4 Investments and funds – an impetus for market growth 43
5.3.2 RESTRAINTS 45
5.3.2.1 Unfavorable reimbursement scenario hinders market growth 45
5.3.2.2 Lack of trained professionals likely to hamper market growth 45
5.3.3 OPPORTUNITIES 46
5.3.3.1 Expansion in Emerging Economies 46
5.3.3.2 Strong product pipeline to propel the market 47

6 GLOBAL NEUROMODULATION MARKET, BY TECHNOLOGY 48
6.1 INTRODUCTION 49
6.2 INTERNAL NEUROMODULATION 50
6.2.1 SPINAL CORD STIMULATION (SCS) 53
6.2.2 DEEP BRAIN STIMULATION (DBS) 54
6.2.3 VAGUS NERVE STIMULATION (VNS) 55
6.2.4 SACRAL NERVE STIMULATION (SNS) 57
6.2.5 GASTRIC ELECTRICAL STIMULATION (GES) 58
6.3 EXTERNAL NEUROMODULATION (NON-INVASIVE) 60
6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 63
6.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 64
6.3.3 RESPIRATORY ELECTRICAL STIMULATION (RES) 65

7 GLOBAL NEUROMODULATION MARKET, BY APPLICATION 67
7.1 INTRODUCTION 68
7.2 SPINAL CORD STIMULATION (SCS) MARKET, BY APPLICATION 69
7.2.1 FAILED BACK SYNDROME (FBSS) 69
7.2.2 CHRONIC PAIN 70
7.2.3 ISCHEMIA 70
7.3 DEEP BRAIN STIMULATION (DBS) MARKET, BY APPLICATION 71
7.3.1 PARKINSON’S DISEASE 71
7.3.2 TREMOR 72
7.3.3 DEPRESSION 72
7.3.4 OTHER DBS APPLICATIONS 72
7.4 SACRAL NERVE STIMULATION MARKET, BY APPLICATION 74
7.4.1 URINE INCONTINENCE 74
7.4.2 FECAL INCONTINENCE 74
7.5 VAGUS NERVE STIMULATION MARKET, BY APPLICATION 75
7.5.1 EPILEPSY 75
7.5.2 OTHER VNS APPLICATIONS 75
7.6 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION 76
7.6.1 GASTROPARESIS 76
7.6.2 OBESITY 77
7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION 78
7.7.1 TREATMENT RESISTANT DEPRESSION 78
7.7.2 OTHER TENS APPLICATIONS 78
7.8 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION 79
7.8.1 DEPRESSION 79
7.8.2 MIGRAINE HEADACHE 79
7.9 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION 80
7.9.1 SPINAL CORD INJURY 80

8 NEUROMODULATION MARKET, BY REGION 81
8.1 INTRODUCTION 82
8.2 NORTH AMERICA 84
8.2.1 U.S. 87
8.2.1.1 Rising prevalence of chronic diseases in the U.S. 87
8.2.1.2 Increasing aging population in the U.S. 87
8.2.1.3 Increasing Lyme disease cases in the U.S. 88
8.2.1.4 Conferences & annual meetings to increase exposure of neuromodulation 88
8.2.2 CANADA 90
8.2.2.1 Increasing incidence of Lyme disease in Canada 90
8.2.2.2 Increasing incidences of cancer and diabetes 90
8.3 EUROPE 92
8.3.1 RAPIDLY AGING POPULATION IN EUROPE 92
8.3.1.1 Conferences & annual meetings to increase exposure to Neuromodulation in the European market 92
8.3.2 GERMANY 96
8.3.2.1 Rising prevalence of Parkinson’s disease in Germany 96
8.3.3 U.K. 98
8.3.3.1 Rising Prevalence of Diabetes in the U.K. 98
8.3.3.2 Rise in CVD prevalence in the U.K. 98
8.3.4 FRANCE 100
8.3.4.1 Rising incidences of Alzheimer’s disease and dementia 100
 
8.3.5 REST OF EUROPE 101
8.3.5.1 High diabetes prevalence in Russia, Turkey, Poland, Romania, and Ukraine 101
8.4 ASIA-PACIFIC 103
8.4.1 JAPAN 106
8.4.1.1 Rising adoption of neurostimulation 106
8.4.2 CHINA 108
8.4.2.1 High diabetes incidences and rapidly aging population 108
8.4.3 INDIA 109
8.4.3.1 Increasing geriatric population & high diabetes incidence 109
8.4.3.2 Conferences on neuromodulation & pain management in India 109
8.4.4 REST OF ASIA-PACIFIC (ROAPAC) 111
8.4.4.1 Increasing prevalence Of Parkinson’s disease in Singapore 111
8.4.4.2 Conferences on neuromodulation in Australia 111
8.5 REST OF THE WORLD 113
8.5.1 INCREASING INCIDENCES OF CANCER IN LATIN AMERICA 114
8.5.2 RISE IN AGING POPULATION & PREVALENCE OF DIABETES 114

9 COMPETITIVE LANDSCAPE 116
9.1 OVERVIEW 116
9.2 MARKET SHARE ANALYSIS, BY KEY PLAYER 116
9.2.1 INTRODUCTION 116
9.3 MEDTRONIC, INC. 117
9.4 BOSTON SCIENTIFIC CORPORATION 118
9.5 ST. JUDE MEDICAL, INC. 119
9.6 COMPETITIVE SCENARIO 120
9.6.1 MARKET DEVELOPMENT 121
9.6.2 AGREEMENTS, COLLABORATIONS, MERGERS, AND PARTNERSHIPS 122
9.6.3 NEW PRODUCT LAUNCHES 123
9.6.4 ACQUISITIONS 124
9.6.5 EXPANSION 125

10 COMPANY PROFILES 126
(Overview, Financials, Products & Services, Strategy, & Developments)*
10.1 INTRODUCTION 126
10.2 MEDTRONIC, INC. 127
10.3 BOSTON SCIENTIFIC CORPORATION 130
10.4 ST. JUDE MEDICAL, INC. 133
10.5 CYBERONICS, INC. 136
10.6 NEVRO CORPORATION 138
10.7 NEUROSIGMA, INC. 140
10.8 NEUROPACE, INC. 142
10.9 BIOCONTROL MEDICAL 144
10.10 SYNAPSE BIOMEDICAL, INC. 146
10.11 NEURONETICS, INC. 148
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

11 APPENDIX 150
11.1 DISCUSSION GUIDE 150
11.2 COMPANY DEVELOPMENTS (2012-2015) 155
11.2.1 MEDTRONIC, INC. 155
11.2.2 BOSTON SCIENTIFIC CORPORATION 155
11.2.3 ST JUDE MEDICAL, INC. 156
11.2.4 NEUROSIGMA, INC. 156
11.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 157
11.4 AVAILABLE CUSTOMIZATIONS 157
11.5 RELATED REPORTS 158